Global prevalence: Multiple myeloma is a common hematologic malignancy worldwide; incidence is higher among the elderly population, and it currently remains incurable.
Staging-based treatment for multiple myeloma
Early treatment (addressing the condition early to control progression and achieve good results)
using chemotherapy combined with targeted drugs can effectively control tumor growth and slow the rate of disease progression.
Intermediate-stage treatment (addressing disease progression, inhibiting spread, and delaying deterioration)
employs a comprehensive approach—combining multi-drug chemotherapy with immunotherapy—to control further disease progression and slow the rate of deterioration.
Advanced-stage treatment (addressing extensive involvement, alleviating symptoms, and prolonging survival)
primarily employs modalities such as chemotherapy, immunotherapy, and stem cell transplantation to alleviate clinical symptoms and maximize patient survival time.
Consequences of failing to receive timely treatment in the early stage: If standardized treatment is not administered promptly in the early stage, the tumor will continue to progress, causing severe bone destruction and renal failure; the optimal window for intervention will be missed, endangering the patient's life.
Why choose Fosun Health for multiple myeloma treatment
Fosun Health’s multiple myeloma diagnosis and treatment services are managed by a specialized hematology-oncology center; the team possesses extensive experience with proteasome inhibitors, immunomodulatory agents, autologous hematopoietic stem cell transplantation, and CAR-T cell therapy.Through a global medical network, patients can access state-of-the-art international treatments such as proteasome inhibitors, CD38 monoclonal antibodies, BCMA-targeted CAR-T cell therapy, bispecific antibodies, and autologous hematopoietic stem cell transplantation.
For complex cases such as relapsed/refractory multiple myeloma, an MDT—comprising experts in hematology, medical oncology, transplantation, and radiology—collaborates to formulate the optimal treatment plan; a cross-border consultation mechanism enables patients to obtain second opinions from leading international hematology centers.
Fosun Health continues to introduce innovative technologies for treating multiple myeloma.FKC389, an off-the-shelf (allogeneic) BCMA/CD19 dual-target CAR-T product developed by Fosun Pharma subsidiary Fosun Kite, has entered clinical trials, offering new hope to patients. The Oncology Center at Foshan Fosun Chancheng Hospital has implemented clinical CAR-T cell therapy;by combining this with systemic treatments—such as autologous hematopoietic stem cell transplantation, proteasome inhibitors, and anti-CD38 monoclonal antibodies—the hospital provides personalized, comprehensive care for myeloma patients at various stages of the disease.
Treatment Methods for Multiple Myeloma
1.Chemotherapy
For newly diagnosed multiple myeloma patients requiring treatment, combination induction therapy based on agents such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and glucocorticoids may be selected based on factors including age, renal function, disease risk, and transplant eligibility.
2.Autologous hematopoietic stem cell transplantation
For patients with multiple myeloma who meet the criteria for transplantation, autologous hematopoietic stem cell collection and transplantation may be performed following induction therapy.
3. CyberKnife precision radiotherapy
For selected patients with localized multiple myeloma presenting with significant symptoms or local lesions in the spine or other bones, CyberKnife precision radiotherapy may be considered based on lesion location and size and the status of surrounding critical structures.
Treatment advantages:
① Precise focusing: High-precision irradiation targeting specific, localized myeloma bone lesions.
② Bone pain relief: Can be used to control local symptoms in cases of localized bone lesions with significant pain.
③ Suitable for spinal lesions: Precise dose planning can be performed for localized spinal lesions based on their relationship with the spinal cord and nerve structures.
④ Reduction of radiation exposure to normal tissue: Minimize radiation exposure to surrounding critical structures through dose optimization.
4.CAR-T cell therapy
For selected patients with relapsed or refractory multiple myeloma who meet the relevant indications, CAR-T cell therapy targeting BCMA or other targets may be evaluated.
Treatment advantages:
① Targeted recognition: T cells genetically engineered to recognize multiple myeloma cells.
② Suitable for relapsed/refractory cases: Applicable for patients whose disease continues to progress despite multiple lines of therapy.
③ Personalized cell therapy: Involves the collection, modification, and expansion of the patient's own T cells.
④ Achievement of deep remission: Some patients may achieve deep disease remission.
5.Bispecific antibody therapy
For selected patients with relapsed or refractory multiple myeloma, bispecific antibody therapy targeting BCMA, GPRC5D, or other targets may be selected based on prior treatment history and specific indications.
6.Bone-protective therapy
For patients with multiple myeloma presenting with bone destruction, bone pain, or risk of fracture, bone-modifying therapies such as bisphosphonates or RANKL inhibitors may be selected based on renal function and skeletal status, combined with necessary local radiotherapy and orthopedic management.
7.Comprehensive therapy
Formulate an individualized comprehensive treatment plan—combining chemotherapy, targeted therapy, immunotherapy, and other modalities based on the patient's specific condition—to enhance therapeutic efficacy.
8.Supportive care
Approaches such as nutritional support, psychological counseling, and symptom management can comprehensively improve the patient's physical condition and quality of life.
Post-treatment care
Maintain a regular daily routine and a high-calcium diet; prevent falls and infections; attend scheduled follow-ups and actively cooperate with further treatment as advised.
Post-treatment examinations
Regular serum protein electrophoresis, bone marrow aspiration, and follow-up imaging are required after treatment to detect changes in the condition in a timely manner.
Conclusion
Multiple myeloma poses a serious threat; the key to treatment lies in early detection, diagnosis, and intervention. Selecting an appropriate treatment plan and adhering to follow-up care helps control disease progression.
